NYSE:GSK - GlaxoSmithKline Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$40.83 +0.37 (+0.91 %)
(As of 08/17/2018 08:57 AM ET)
Previous Close$40.46
Today's Range$40.64 - $40.9967
52-Week Range$34.52 - $42.36
Volume2.60 million shs
Average Volume3.23 million shs
Market Capitalization$99.57 billion
P/E Ratio14.18
Dividend Yield4.99%
Beta0.84
GlaxoSmithKline logoGlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; and a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GSK
CUSIPN/A
Phone44-20-8047-5000

Debt

Debt-to-Equity Ratio8.13
Current Ratio0.94
Quick Ratio0.61

Price-To-Earnings

Trailing P/E Ratio14.18
Forward P/E Ratio13.89
P/E Growth1.98

Sales & Book Value

Annual Sales$38.89 billion
Price / Sales2.60
Cash Flow$3.9034 per share
Price / Cash10.46
Book Value$1.81 per share
Price / Book22.56

Profitability

EPS (Most Recent Fiscal Year)$2.88
Net Income$1.97 billion
Net Margins5.51%
Return on Equity159.74%
Return on Assets10.40%

Miscellaneous

Employees99,827
Outstanding Shares2,479,930,000
Market Cap$99.57 billion

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Wednesday, July 25th. Shareholders of record on Friday, August 10th will be given a dividend of $0.496 per share on Thursday, October 11th. This represents a $1.98 dividend on an annualized basis and a yield of 4.86%. The ex-dividend date is Thursday, August 9th. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) issued its quarterly earnings results on Wednesday, July, 25th. The pharmaceutical company reported $0.77 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.71 by $0.06. The pharmaceutical company had revenue of $9.95 billion for the quarter, compared to analysts' expectations of $9.47 billion. GlaxoSmithKline had a return on equity of 159.74% and a net margin of 5.51%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, October, 24th 2018. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

13 analysts have issued 12 month target prices for GlaxoSmithKline's shares. Their forecasts range from $35.85 to $40.00. On average, they expect GlaxoSmithKline's stock price to reach $38.9625 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Price Targets for GlaxoSmithKline.

What is the consensus analysts' recommendation for GlaxoSmithKline?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma Walmsley, CEO & Director (Age 48)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 54)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55)

Has GlaxoSmithKline been receiving favorable news coverage?

News coverage about GSK stock has been trending somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlaxoSmithKline earned a coverage optimism score of 0.24 on Accern's scale. They also assigned media stories about the pharmaceutical company an impact score of 48.16 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for GlaxoSmithKline.

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (0.76%), Fisher Asset Management LLC (0.56%), Renaissance Technologies LLC (0.38%), Bank of America Corp DE (0.31%), Bank of New York Mellon Corp (0.24%) and Federated Investors Inc. PA (0.18%). View Institutional Ownership Trends for GlaxoSmithKline.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including OLD Republic International Corp, Connor Clark & Lunn Investment Management Ltd., FMR LLC, Confluence Investment Management LLC, Chartwell Investment Partners LLC, Bruderman Asset Management LLC, Anchor Capital Advisors LLC and Ariel Investments LLC. View Insider Buying and Selling for GlaxoSmithKline.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, South Texas Money Management Ltd., Fisher Asset Management LLC, Cornerstone Wealth Management LLC, BlackRock Inc., Bank of New York Mellon Corp and Canada Pension Plan Investment Board. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $40.83.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $99.57 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  448 (Vote Outperform)
Underperform Votes:  783 (Vote Underperform)
Total Votes:  1,231
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.